Heart failure startup emerges with $42 million in financing for its intelligent fluid management system
Amount Raised
$42 Million
Round Type
Series A
MilfordHealthcareHealth CareInvestors
Description
Reprieve Cardiovascular Inc. announced a $42 million Series A financing round to advance clinical trials for its automated diuretic and fluid management treatment for acute decompensated heart failure (ADHF). The funding will advance the company’s clinical programs, including the ongoing FASTR trial and its upcoming pivotal trial, and reinforce the belief in the need for a new technology to improve the lives of patients suffering from ADHF around the world.
Who to call at Reprieve Cardiovascular, and when
A new round usually means Reprieve Cardiovascular is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Reprieve Cardiovascular raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Reprieve Cardiovascular, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Reprieve Cardiovascular. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Reprieve Cardiovascular raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansReprieve Cardiovascular raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.